Di­anthus marks Nas­daq de­but with PhI hit; Ar­bu­tus shuts oral RNA and coro­n­avirus pro­grams

As Di­anthus Ther­a­peu­tics starts trad­ing on Nas­daq, it’s al­so mark­ing an­oth­er mile­stone with pos­i­tive Phase I safe­ty and phar­ma­co­ki­net­ic da­ta.

DNTH103, a se­lec­tive in­hibitor of the ac­tive form of the C1s pro­tein, was shown to block the clas­si­cal path­way and have a 60-day half-life when giv­en to 52 healthy vol­un­teers. With the pro­file con­firmed, Di­anthus plans to start mul­ti­ple Phase II tri­als in var­i­ous neu­ro­mus­cu­lar dis­eases next year, start­ing with gen­er­al­ized myas­the­nia gravis and then mul­ti­fo­cal mo­tor neu­ropa­thy and chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER